

Diazyme launches beta-hydroxybutyrate assay

June 8, 2021—[Diazyme](#) launched its FDA 510(k)-exempt Beta-Hydroxybutyrate Assay for the quantitative determination of beta-hydroxybutyrate. BHB serves as a guide for monitoring the progress of insulin therapy for diabetic ketoacidosis and for patients presenting to the emergency room with documented hypoglycemia, acidosis, alcohol ingestion, or an unexplained increase in the anion gap.

The enzymatic BHB assay is a dual-vial, liquid-stable reagent designed for use on clinical chemistry analyzers. The assay uses a 2- μ L sample volume of human serum or plasma and has a limit of detection of .006 mmol/L. Reagent stability is four weeks when stored at 2°–8°C.